Cytek Biosciences (CTKB) Q2 FY26 earnings call

Cytek Biosciences reported solid Q2 FY26 results, driven by robust revenue growth in the US and China, alongside the successful launch of two new high-end flow cytometry instruments. The company is undergoing a strategic reorganization into three customer-aligned business units to enhance market penetration and optimize resource allocation. While facing headwinds in EMEA and parts of APAC, management remains focused on expanding its recurring revenue base and leveraging technological leadership for sustainable long-term growth.